Vertex Reports meta-analysis Data for Reslizumab in Ankylosing spondylitis

Vertex today announced meta-analysis results for reslizumab in patients with ankylosing spondylitis. The study demonstrated that reslizumab reduces adverse events compared to standard of care or placebo. These results provide important insights into the treatment of ankylosing spondylitis and support the continued development of reslizumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.